GoKawiilArgenx stock drops 18% after halting Vyvgart trial for autoimmune disease
Argenx announced the suspension of a late-stage clinical trial for its autoimmune treatment, Vyvgart, citing insufficient efficacy. The company's shares declined sharply, erasing all gains made earlier in the year.